Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.

about

Mechanism and Management of Cancer Chemotherapy-Induced Atherosclerosis

P2860

Q58791422-A92CAFE2-6184-448F-89BB-AD0B3036F9A3

P2860

Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.

Item

http://www.wikidata.org/entity/Q52641875

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Ponatinib efficacy and safety ...... lts of the phase 2 PACE trial.

@en

Ponatinib efficacy and safety ...... lts of the phase 2 PACE trial.

@nl

type

Item

label

Ponatinib efficacy and safety ...... lts of the phase 2 PACE trial.

@en

Ponatinib efficacy and safety ...... lts of the phase 2 PACE trial.

@nl

prefLabel

Ponatinib efficacy and safety ...... lts of the phase 2 PACE trial.

@en

Ponatinib efficacy and safety ...... lts of the phase 2 PACE trial.

@nl

P1476

Ponatinib efficacy and safety ...... lts of the phase 2 PACE trial.

@en

P2093

Charles Chuah

http://www.w3.org/2001/XMLSchema#string

Daniel J DeAngelo

http://www.w3.org/2001/XMLSchema#string

Delphine Rea

http://www.w3.org/2001/XMLSchema#string

Dong-Wook Kim

http://www.w3.org/2001/XMLSchema#string

Franck E Nicolini

http://www.w3.org/2001/XMLSchema#string

Frank G Haluska

http://www.w3.org/2001/XMLSchema#string

H Jean Khoury

http://www.w3.org/2001/XMLSchema#string

Jane F Apperley

http://www.w3.org/2001/XMLSchema#string

Javier Pinilla-Ibarz

http://www.w3.org/2001/XMLSchema#string

Martin C Müller

http://www.w3.org/2001/XMLSchema#string

P2860

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

Ponatinib in refractory Philadelphia chromosome-positive leukemias.

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.

Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results.

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias

Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.

Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients.

P31

scholarly article

P356

10.1182/BLOOD-2016-09-739086

http://www.w3.org/2001/XMLSchema#string

P407

English

P50

Carlo Gambacorti-Passerini

P577

2018-03-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29567798

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

6071555

http://www.w3.org/2001/XMLSchema#string

Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.

about

P2860

P2860

Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P407

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P31

P356

P407

P50

P577

P698

P921

P932